Teva Pharmaceuticals Issues Statement on a Statement by U.S. Department of Health and Human Services Secretary Kathleen Se

NORTH WALES, Pa.--(BUSINESS WIRE)-- We commend the FDA for making the recommendation to approve providing women with increased over-the-counter (OTC) access to Plan B One-Step® and we are disappointed that at this late date, the Department of Health and Human Services has come to a different conclusion. We have not yet received the Complete Response Letter at this time. We will review the letter when we receive it and then determine our next steps.



CONTACT:

Media:
Teva USA
Denise Bradley, 215-591-8974
[email protected]

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Health  FDA  General Health

MEDIA:

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.